CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

Autoria(s): Ni, J; Cozzi, P J; Hao, J L; Beretov, J; Chang, L; Duan, W; Shigdar, S; Delprado, W J; Graham, P H; Bucci, J; Kearsley, J H; Li, Y
Data(s)

01/05/2014
Resumo

Prostate cancer (CaP) is the second leading malignancy in older men in Western countries. The role of CD44 variant 6 (CD44v6) in CaP progression and therapeutic resistance is still uncertain. Here, we investigated the roles of CD44v6 in CaP metastasis and chemo/radioresistance. Expression of CD44v6 in metastatic CaP cell lines, human primary CaP tissues and lymph node metastases was assessed using immunofluorescence and immunohistochemistry, respectively.
Identificador

http://hdl.handle.net/10536/DRO/DU:30067330
Idioma(s)

eng
Publicador

Wiley-Blackwell
Relação

http://dro.deakin.edu.au/eserv/DU:30067330/duan-CD44variant-2014.pdf

http://www.dx.doi.org/10.1002/pros.22775

http://www.ncbi.nlm.nih.gov/pubmed/24615685
Direitos

2014, Wiley-Blackwell
Palavras-Chave #CD44 variant 6 #PI3K/Akt/mTOR pathway #Wnt pathway #chemoresistance #prostate cancer #radioresistance #Science & Technology #Life Sciences & Biomedicine #Endocrinology & Metabolism #Urology & Nephrology #EPITHELIAL-MESENCHYMAL TRANSITION #STEM-CELLS #PANCREATIC-CANCER #INITIATING CELLS #PROGNOSTIC VALUE #DRUG-RESISTANCE #EXPRESSION #IDENTIFICATION #PROGRESSION #DOCETAXEL
Tipo

Journal Article
Acesso ao item digital